VistaGen
Therapeutics is a biotechnology company whose focus is on applying pluripotent
stem cell technology for drug rescue and regenerative medicine. The company,
which is based out of San Francisco, has been in the business of human
pluripotent stem cell (hPSC) technology for over 16 years.
Human pluripotent
cells are the building blocks of all cells of the human body. VistaGen believes
that controlling the differentiation of these kinds of cells can make stronger
and better cells that will benefit drug rescue and regenerative medicine
initiatives.
VistaGen’s approach
to drug rescue and regenerative medicine is unique because of the products the
company chooses to work with. It selects drug candidates that have been
abandoned by other biotechnology and pharmaceutical companies and uses its
technology to generate new chemical variants of them.
These candidates are
perfectly usable, but were abandoned before the market approval stage because
of concerns related to their effect on patients’ hearts and livers.
VistaGen is
confident it can rework these abandoned candidates into something usable, with
an end goal of creating a pipeline of Drug Rescue Variants™. These Variants can
then be sold to biotechnology and pharmaceutical companies who can then develop
them, get them approved, and then sell them commercially.
VistaGen shared
exciting news in April 2014 when it found out that it had received a Notice of
Allowance from the United States Patent and Trademark Office regarding an
application for a patent to expand one of its technology platforms, LiverSafe
3D™. The patent will expand VistaGen’s intellectual property portfolio to stem
cell culture systems that produce cells for the liver, lung, pancreas, and
thyroid. The company believes that LiverSafe 3D™ will benefit from this
expanded intellectual platform.
For more
information, please visit www.vistagen.com.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VistaGen
Therapeutics is a biotechnology company whose focus is on applying pluripotent
stem cell technology for drug rescue and regenerative medicine. The company,
which is based out of San Francisco, has been in the business of human
pluripotent stem cell (hPSC) technology for over 16 years.
Human pluripotent
cells are the building blocks of all cells of the human body. VistaGen believes
that controlling the differentiation of these kinds of cells can make stronger
and better cells that will benefit drug rescue and regenerative medicine
initiatives.
VistaGen’s approach
to drug rescue and regenerative medicine is unique because of the products the
company chooses to work with. It selects drug candidates that have been
abandoned by other biotechnology and pharmaceutical companies and uses its
technology to generate new chemical variants of them.
These candidates are
perfectly usable, but were abandoned before the market approval stage because
of concerns related to their effect on patients’ hearts and livers.
VistaGen is
confident it can rework these abandoned candidates into something usable, with
an end goal of creating a pipeline of Drug Rescue Variants™. These Variants can
then be sold to biotechnology and pharmaceutical companies who can then develop
them, get them approved, and then sell them commercially.
VistaGen shared
exciting news in April 2014 when it found out that it had received a Notice of
Allowance from the United States Patent and Trademark Office regarding an
application for a patent to expand one of its technology platforms, LiverSafe
3D™. The patent will expand VistaGen’s intellectual property portfolio to stem
cell culture systems that produce cells for the liver, lung, pancreas, and
thyroid. The company believes that LiverSafe 3D™ will benefit from this
expanded intellectual platform.
For more
information, please visit www.vistagen.com.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment